Evidence map›Paper›PMID 37440119›Full record

ArticleNeurochemical research2023

Correction to: Luvadaxistat: A Novel Potent and Selective D-Amino Acid Oxidase Inhibitor Improves Cognitive and Social Deficits in Rodent Models for Schizophrenia.

Rosa Fradley, Pascal Goetghebeur, David Miller, Russell Burley, Sarah Almond, Agnès Gruart I Massó, José M Delgado García, Bin Zhu, Eimear Howley, Jo C Neill and 6 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurochemical research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 5 institutions in 4 countries.

Rosa FradleyNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
Pascal GoetghebeurNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
David MillerNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
Russell BurleyNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
Sarah AlmondNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
Agnès Gruart I MassóDivision of Neurosciences, Pablo de Olavide University, Seville, Spain.
José M Delgado GarcíaDivision of Neurosciences, Pablo de Olavide University, Seville, Spain.
Bin ZhuNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
Eimear HowleyNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
Jo C NeillDivision of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester, UK.
Ben GraysonDivision of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester, UK.
Philip GaskinNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
Mark CarltonNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
Ian GrayNeuroscience Drug Discovery Unit, Takeda, Cambridge, UK.
Jordi SerratsNeuroscience Drug Discovery Unit, Takeda California, 9625 Towne Centre Dr, San Diego, CA, 92121, USA. jordiserrats@gmail.com.
Ceri H DaviesTakeda Pharmaceuticals Company Limited, Fujisawa, Kanagawa, Japan.
Takeda (United Kingdom) · GBManchester Academic Health Science Centre · GBUniversidad Pablo de Olavide · ESTakeda (Japan) · JPTakeda (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37440119
PMCPMC10514168
OpenAlexW4384120404

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.